A carregar...
Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non–Small Cell Lung Cancer
IMPORTANCE: The prevalence of early-stage non–small cell lung cancer (NSCLC) is expected to increase with recent implementation of annual screening programs. Reliable prognostic biomarkers are needed to identify patients at a high risk for recurrence to guide adjuvant therapy. OBJECTIVE: To develop...
Na minha lista:
| Publicado no: | JAMA Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Medical Association
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5710196/ https://ncbi.nlm.nih.gov/pubmed/28687838 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.1609 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|